Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.44 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016275 | 1.00 | PTPN1 (0.50) | PTPN1GSK3BVNN1LOXL2LOX | |
| SCHEMBL29227517 | 0.83 | DDR1 (0.46) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL25334034 | 0.81 | PLOD2 (0.61) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL29227518 | 0.81 | VNN1 (0.44) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL28019417 | 0.80 | VNN1 (0.58) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL16632312 | 0.80 | VNN1 (0.43) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL503171 | 0.79 | KDM5C (0.55) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL29427285 | 0.79 | KDM5C (0.55) | VNN1LOXL2LOXSMARCA2SMARCA4 | |
| SCHEMBL30989557 | 0.79 | GSK3B (0.52) | PTPN1GSK3B | |
| SCHEMBL19434309 | 0.77 | PTPN1 (0.50) | PTPN1GSK3BLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| CN-116134035-A | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-2970201-B1 | 6-[4-(1H-IMIDAZOL-2-YL)PIPERIDIN-1-YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9867826-B2 | Heterocycles as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| US-20160361316-A1 | NOVEL HETEROCYCLES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9458134-B2 | Heterocycles as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20160016936-A1 | NOVEL HETEROCYCLES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2970201-A1 | 6-[4-(1 H-IMIDAZOL-2-YL)PIPERIDIN-1 -YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014143612-A1 | 6-[4-(1 H-IMIDAZOL-2-YL)PIPERIDIN-1 -YL]PYRIMIDIN-4-AMINE DERIVATIVES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361316-A1 | NOVEL HETEROCYCLES AS MODULATORS OF KINASE ACTIVITY | MAP3K20, MAP3K19, MAP3K15 | PTPN1 1099/4885GSK3B 588/4885VNN1 4355/4885 |
| US-20160016936-A1 | NOVEL HETEROCYCLES AS MODULATORS OF KINASE ACTIVITY | MAP3K20, MAP3K19, MAP3K15 | PTPN1 1099/4885GSK3B 588/4885VNN1 4355/4885 |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | KLKB1, F2, SERPINC1 | PTPN1 2296/4885GSK3B 1699/4885VNN1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.